ARMP Latest Press Releases

-- October 7, 2026 --

Armata Pharmaceuticals Strengthens Intellectual Property Portfolio with Two Recent Patent Issuances in the United States PRNewswire 7:00 AM

-- September 23, 2026 --

Armata Pharmaceuticals Receives $3.7 Million in Additional Non-Dilutive Funding from U.S. Department of War to Support Advancement of AP-SA02 Phase 3 Development PRNewswire 7:00 AM

-- September 21, 2026 --

Armata Pharmaceuticals to Present Data at ISSSI 2026 Showing Defined Genetic Diversity in AP-SA02 May Enhance Killing of Certain Staphylococcus aureus Clinical Isolates PRNewswire 7:00 AM

-- September 14, 2026 --

Armata Pharmaceuticals Receives U.S. FDA Breakthrough Therapy Designation for AP-SA02 PRNewswire 7:01 AM

-- September 10, 2026 --

Armata Pharmaceuticals to Participate in the H.C. Wainwright 28th Annual Global Investment Conference PRNewswire 7:00 AM

-- September 3, 2026 --

Armata Pharmaceuticals Announces New Publication That Advances Understanding of Phage Biology to Support Development of Next-Generation Antibacterials PRNewswire 7:00 AM

-- August 12, 2026 --

Armata Pharmaceuticals Announces Financial Results for the Second Quarter 2026 and Provides a Corporate Update PRNewswire 4:05 PM

-- July 20, 2026 --

Armata Pharmaceuticals Achieves Key Progress Across Clinical, Regulatory and Manufacturing Activities Supporting Planned Phase 3 Initiation of AP-SA02 PRNewswire 7:00 AM

-- July 13, 2026 --

Armata Pharmaceuticals Receives Agreement from FDA on Initial Pediatric Study Plan for AP-SA02 for the Treatment of Complicated Staphylococcus aureus Bacteremia PRNewswire 7:00 AM

-- June 23, 2026 --

Armata Pharmaceuticals Receives $2.5 Million of Additional Non-Dilutive Award Funding from the U.S. Department of Defense to Support AP-SA02 PRNewswire 7:00 AM

Market Data Delayed 15 Minutes